Actively Recruiting
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Led by Tata Memorial Hospital · Updated on 2026-02-04
110
Participants Needed
1
Research Sites
222 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.
CONDITIONS
Official Title
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and above
- Ability to tolerate full course of pelvic radiotherapy with or without chemotherapy and brachytherapy
- Ability to understand and willing to sign informed consent
- Willing to undergo extra biopsies and blood sample collections for research
- Diagnosed with locally advanced cervical cancer (LACC) Stage IB2 to IIIC1 for radical treatment cohort
- Diagnosed with Stage IIIB to IVA cervical cancer if palliative radiotherapy is indicated
- No previous pelvic irradiation or chemotherapy for radical and palliative cohorts
- Diagnosed with LACC Stage IIIC2 for cohort B
- Diagnosed with gynecological cancer requiring in-field radiation and planned for reirradiation for cohort C
You will not qualify if you...
- Severe medical condition preventing complete treatment delivery
- Immunocompromised state or active infection
- Taking immunosuppressive drugs for other medical conditions
- Receiving immune checkpoint inhibition therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tata Memorial Centre
Mumbai, Maharashtra, India, 400012
Actively Recruiting
Research Team
D
Dr. Supriya Chopra
CONTACT
M
Mr. Tanmay Wairkar
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here